Synchronoss Technologies, Inc. (NASDAQ:SNCR) slipped over -0.62% at $14.36, after hitting low of $14.11 in an intra-day trade. Synchronoss Technologies, Inc. has 46.42 million shares outstanding, and in the last trade has seen ATR around 0.94. The volume of SNCR witnessed a shift from 2.22 million shares, based on a 50-day average, to 1.53 million shares.
In the most updated research from a number of analysts on Wall Street, the company gets 0 Buys and 2 Sell among 5 analysts. Synchronoss Technologies, Inc. (NASDAQ:SNCR) recently traded as high as $14.55. The consensus analyst target price is $16. That gives us a street projected return of 11.42%. If the published price targets set by Synchronoss Technologies, Inc. analysts have any power to influence the stock’s share price, the highest price target set for SNCR is $25.
Synchronoss Technologies, Inc. most recently reported earnings per share (EPS) of $0.24 for the June 2017 versus $0.61 in the same quarter last year, representing -61% growth. Analysts had predicted $0.26. Revenue during the quarter was $123.87 million, representing -21% growth from $157.78 million in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as -8% to the downside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.
On a similar note, analysts expect EPS of $0.25 in September 2017 quarter and $0.3 in December 2017 quarter, representing -55.36% and 233.33% growth, respectively. They expect this year’s earnings to fall -2.82% year-over-year to $0.69, followed by 36.23% growth in the next year to $0.94.
Shares of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) traded down -0.61% in the last session while performance was up 0.16% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $0.1823 while enlarging the period to 200 trading days, the average price was $0.2486. Currently, 216.94 million total shares are owned by the public and among those 147.9 million shares have been available to trade. The percentage of shares being held by the company management was 30.22% while institutional stake was 42.6%.
Northwest Biotherapeutics, Inc. (NWBO) is recuperating from the fall at $0.14, the 52-week low. The stock has risen 1.88% since then. The trading saw a strength at $0.98 , the 52-week high. But since then, those gains have faded by -32.08%. NWBO has lost -5.48% in the 1-month period.
Synchronoss Technologies, Inc. has a beta of 0, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.73 a share in the trailing twelve months. It last reported revenues of $0 and EPS of -$0.65 for the June 2017, representing -100% top-line growth and EPS growth.
Looking forward, the company’s quarterly earnings in the three months through September 2017 and in the quarter ending December 2017, reflecting -356886% and -499600% growth, respectively. For the full year, analysts expect earnings to decline -113623% yoy. Next year this decline will reach 0%.